PAMP
PCRX icon

Polar Asset Management Partners’s Pacira BioSciences PCRX Stock Holding History

Polar Asset Management Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,783
Closed -$753K – 953
2023
Q2 		$753K Sell
18,783
-213,100
-92% -$8.81M 0.01% 537
2023
Q1 		$9.46M Buy
+231,883
New +$9.23M 0.14% 200

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Polar Asset Management Partners's PCRX Position: Q3 2023 in Review

Polar Asset Management Partners sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 18,783 shares — an estimated $753K sold.

Polar Asset Management Partners first reported a position in PCRX in Q1 2023 and held it in 2 quarters. The position peaked at $9.46M in Q1 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

  • Polar Asset Management Partners reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
  • Polar Asset Management Partners sold 18,783 Pacira BioSciences shares in Q3 2023, an estimated $753K.
  • Polar Asset Management Partners first reported a position in Pacira BioSciences in Q1 2023 and held it in 2 quarters.
  • Polar Asset Management Partners's Pacira BioSciences position peaked at $9.46M in Q1 2023.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Polar Asset Management Partners's 13F filing for Q3 2023, filed 14 Nov 2023.